The following material is intended for UK professional keepers of animals, UK veterinary surgeons and SQPs only. By continuing to browse this site, you confirm that this describes you.
New vaccine already has a proven record
Zoetis’ recently launched Suvaxyn® Circo+MH RTU vaccine may be new to the UK market, but it has been used successfully in North America for more than two years, with many millions of doses having been sold
Introduced to provide protection against the economically important diseases associated with Porcine Circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo), the latest addition to Zoetis’ range of pig vaccines has arrived in Europe with a wealth of user experience from the US and Canada. Marketed here as Suvaxyn Circo+MH RTU*, this single-bottle, single-shot combined product has been used successfully on the other side of the Atlantic since it was launched there at the beginning of 2014.
The fact that the vaccine is ready-to-use proved a big attraction to North America’s pig managers, who appreciated the benefits of switching a one-bottle, one-dose combination vaccine for PCV2 and M. hyo on the market there.
“Pig producers the world over have the same focus on efficiency, and the convenience of protecting pigs against these two costly diseases in a single shot at weaning is very attractive purely in terms of the time saved,” Zoetis’ UK Pig and Poultry Director, Ben Lacey, says. “It gave the new vaccine an immediate advantage over using two separate products, as well as competing combined vaccines that either require a two-dose regime or a two-bottle approach where the components have to be mixed before use.
“And you can not ignore the fact that a single dose is better for the pigs and farm staff too; the reduced handling reduces stress on the piglets during the crucial weaning period, while reducing the number of injections means less risk of accidents involving the stockmen.”
The effectiveness of the vaccine’s innovative formulation has also impressed both farmers and vets in North America. Suvaxyn Circo+MH RTU has been created from scratch, rather than simply mixing two existing vaccines, and has employed concepts and processes used in the manufacture of human medicines. This approach has resulted in a product that only produces minimal injection reactions in the pigs, but then goes on to reliably provide the protection required against both PCV2 and M. hyo. As it is exactly the same vaccine now being introduced into the UK and rest of Europe, pig producers here can expect the same results.
One early adopter of the new Zoetis vaccine was David Hardin, who runs a 600-sow farrow-to-finish unit near Danville, Indiana. It is a family operation that he runs with his father and three staff. The farm, which has DanBred sows bred to a PIC terminal sire, is currently achieving 26 pigs/sow/year, which is a level of performance David is content with.
“Our farm facilities are a little older, at about 20-years old, and newer operations with better facilities would probably get a little bit better numbers than that,” he says, “But we like to think that we can still compete, as long as we have access to the best genetics, and best technologies.”
The family takes the finishers up to about 120kg liveweight, and they dress out to leave a carcase of about 90kg. “We never have a market pig that will make it to its six-month birthday,” David says, “and the vast majority of the hogs that we sell are gone by 24 weeks.”
The Hardin operation has been using Suvaxyn Circo+MH RTU exclusively since they switched to it about two-years ago.
“Prior to the development of any of the commercially available Circovirus vaccines, we had been experiencing very, very bad symptoms where, in a lot of groups,” David says. “We were experiencing combined mortality and morbidity upwards of 15 to 20%, so it was definitely hurting us from both a production and financial standpoint.
“And as far as M. hyo is concerned, it is prevalent enough in the US that I think it would be unwise to try and get by without vaccination.
“I would say we have been very happy with the performance of the vaccine. We are giving a single-dose when we wean at three weeks of age, and we are very happy with the control of both PCV2 and M. hyo.”
About 900 miles to the North-east of Danville, in the Canadian province of Quebec, Dr Charles Surprenant is a veterinary practitioner working with F Ménard, a family-owned integrated production operation processing between 4,500 to 5,000 pigs per day. The business produces the feed and the pigs, as well as having a slaughter plant, so it owns all of the process except the multiplication and rearing farms that it engages under contract.
“We operate what we call a three-site system,” Charles says. “We have relatively large sow barns, of 1,500 up to 5,000 sows, producing piglets. We wean at about 20- 21 days and the pigs are moved to a nursery site. They spend six weeks there, and after that are moved into finisher buildings on yet another site.
“It is quite a simple system and there are now 24 different production pyramids in the company. The pigs are never mixed, so the weaners from one sow barn are all kept together right up to marketing. There may be pigs from different pyramids on the same site, but each pyramid’s pigs will be kept in dedicated buildings.”
The pigs are usually finished at 25 to 27 weeks, with the company looking for a carcase between 125 to 135kg liveweight and a carcase weight of between 100 to 108kg.
The scale of F Ménard’s business means that it prefers to deal with all the major animal health companies, so when Suvaxyn Circo+MH RTU was launched, the company immediately put it into one pyramid so they could learn more about the product.
“We have used it for a bit more than two years now,” Charles says. “We treat one pyramid producing 2,000 piglets every week from a barn with 3,600 PIC sows bred to the PIC 380 terminal boar. Situated in New Brunswick, in Eastern Canada, it is a 10- hour drive from the sow barn to the nursery site, and the 6kg piglets are vaccinated with a single dose on arrival after the journey.
“The sows in this pyramid produce one of our better pig flows. The herd is free from everything because it is so remote; there are no other sows around. They produce about 28 pigs/sow/year, which is above average for our business.
“Having vaccinated more than 200,000 weaners with Suvaxyn Circo+MH RTU, we have never had any issues or bad reactions with the injections, and we are very satisfied with the product so far in our situation. We never have any issues with M. hyo; and we have seen no manifestations of the presence of PCV2 in the finishing barns or at the processing plant whatsoever.”
More information on Suvaxyn Circo+MH RTU can be found online at: www.suvaxynoneshot.co.uk
Suvaxyn® Circo+MH RTU
Single-shot, ready-to-use combined vaccine
Administered from three weeks of age
Reduces faecal shedding caused by PCV2 infection
Reduces viral load in blood and lymphoid tissues caused by PCV2 infection
Reduces lung lesions caused by M. hyo infection
Onset of immunity is three weeks
Dosage of 2ml by intramuscular injection in the neck or behind the ear
*Marketed as Fostera PCV MH in the US and Canada
Suvaxyn. Circo+MH RTU Emulsion for Injection for Pigs contains inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein and inactivated Mycoplasma hyopneumoniae, strain P-5722-3. For active immunisation of pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae. POM-V
For further information please see the product’s SPC or please contact your veterinary surgeon or Zoetis UK Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. www.zoetis.co.uk Customer Support: 0845 300 8034. Use medicines responsibly (www.noah.co.uk/responsible). Date of preparation: October 2016. AH640/16
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.